Citius Pharmaceuticals
Cranford
About Citius Pharmaceuticals
Citius Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapeutic products for large and growing markets. Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve market position or market exclusivity. By using previously approved drugs with substantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development. Citius is advancing two proprietary product candidates, our Mino-Lok™ product and a Hydrocortisone-Lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $204.7M
- Funding stage: IPO
- Last round: Grant (Feb 2026)
- Ticker: nasdaq:CTXR
- Website: citiuspharma.com
- Phone: (908)967-6677
Industries & Categories
Biotechnology, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/citius-pharmaceuticals-122443 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.